TriVascular Technologies, which has developed a new stent graft platform to treat aortic aneurysms, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The Santa Rosa, CA-based company, which was founded in 1998 and booked $20 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol TRIV. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
